Position in AZN
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$30,338
New position
Shares Held
160
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.10%
of 13F equity value
Holder Rank
#1,319
of 1,459 holders
Holding Since
Jun 2026
1 quarter on record
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Regatta Research & Money Management holds $1,200,114 across 8 Drug Manufacturers - General names. AZN ranks #7 (2.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PFE |
Pfizer Inc
|
15,106 | $363,750 | |
| 2 | AMGN |
Amgen Inc
|
687 | $248,775 | |
| 3 | LLY |
ELI LILLY & Co
|
199 | $238,685 | |
| 4 | JNJ |
Johnson & Johnson
|
714 | $181,332 | |
| 5 | ABBV |
AbbVie Inc.
|
327 | $82,284 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
260 | $32,848 | |
| 7 | AZN |
Astrazeneca PLC
This page
|
160 | $30,338 | |
| 8 | MRK |
Merck & Co., Inc.
|
172 | $22,102 |
All Filings in AZN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $30,338 | 160 | Shares | Sole | 2026-08-12 | |
| No filing history on record for this holder in this stock. | ||||||